Treating Addiction: Alcohol Abuse Treatment Centers Part 2
Disulfiram pharmaceutical therapy can be a very effective addition to a coherent treatment in Alcohol Treatment Centers program which also integrates methods to assist individuals in the process of adhesion to the longer term regimen of regularly scheduled doses of disulfiram, as well as increasing the motivation for adherence and to encourage the prevention of future relapses.
It is always problematical to be able to compare various research studies which are attempting to determine statistical factual data based on differences in methodologies and the natural variability within the subject groups. There exist various research studies where the individuals were literally forced into treatment in Alcohol Treatment Centers with oral disulfiram. Oral disulfiram seems to have an edge over the implanted disulfiram when administered in a coherent strategy specifically with individuals involved in a series of effective programs.
The clinical evidence points to the finding that clients who already benefit from an elevated level of social stability are likely to gain greater positive results from disulfiram than others. Research points to the discovery that individuals who were already strongly motivated and meticulously compliant with the treatment in Alcohol Treatment Centers process also witness more positive results from the drugs administered as part of their therapy than others.
Clinical research into the various antidipsotropic medications which were in common use years ago has demonstrated that these particular older drugs are not particularly effective. The clinical basis for the utilization of calcium carbimide and metronidazole showed that the effects were so slight as to evade definitive results.
Anti-crave Substance Therapy
Medications which are frequently utilized for this specific purpose are zimelidine, fluoxetine, and citalopram. Extensive and medically accurate clinical trials using these pharmaceuticals with moderately dependent individuals who are not currently suffering from depressive episodes have shown that they can be responsible for minimized short-term substance intake by approximately 20%.
There are other drugs such as 5-HT agonist buspirone and 5-HT antagonist ritansarin that may reduce the sensation of craving, however, these conclusions are plagued by the inconsistent results of the current controlled trials which have found no variables in results in either non-depressed individuals or ones suffering from depression when statistically calculated against a control group utilizing only placebos.
Naltrexone is yet another medication that has been utilized in recent studies analyzing the situation of social and extreme alcohol drinkers receiving treatment. Naltrexone is an opiate form of an antagonist which has the beneficial effect in the individual patient to reduce craving for the various alcoholic beverages. A number of clinical trials and various medical studies with subjects who are alcohol-dependent, it was shown that those individuals who were receiving naltrexone consumed alcohol on fewer occasions and experienced a lower percentage of relapse to extreme alcohol consumption than those individuals in the clinical trial who were administered only a placebo. Naltrexone is approved for utilization in alcohol treatment in Alcohol Treatment Centers in North America and acceptance of this medication is growing in clinical institutions around the world. Naltrexone has now been widely acknowledged as a valid component of a coherent strategy of treatment.